Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03532451
Title Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (PrE0807)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors PrECOG, LLC.
Indications

bladder urothelial carcinoma

Therapies

Lirilumab + Nivolumab

Nivolumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.